GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » EPS without NRI

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) EPS without NRI : $-9.07 (TTM As of Sep. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals EPS without NRI?

Eloxx Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-1.49. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.07.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Eloxx Pharmaceuticals's EPS without NRI or its related term are showing as below:

ELOX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -120   Med: 12.35   Max: 64.5
Current: 32.4

ELOX's 3-Year EPS without NRI Growth Rate is ranked better than
80.32% of 1296 companies
in the Biotechnology industry
Industry Median: 5.5 vs ELOX: 32.40

Eloxx Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2023 was $-1.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.07.

Eloxx Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2023 was $-1.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.07.


Eloxx Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Eloxx Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals EPS without NRI Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.38 -53.84 -30.35 -38.46 -16.63

Eloxx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.48 -2.95 -2.68 -1.94 -1.49

Competitive Comparison of Eloxx Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Eloxx Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's PE Ratio without NRI falls into.



Eloxx Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eloxx Pharmaceuticals  (OTCPK:ELOX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eloxx Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Executives
Sumit Aggarwal director, officer: PRESIDENT AND CEO 480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur officer: HEAD OF R&D C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski director C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib director 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra director C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur director 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts director 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p. 10 percent owner 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Headlines

From GuruFocus

Eloxx Pharmaceuticals Announces Changes to Board of Directors

By PurpleRose PurpleRose 07-15-2022